CO2 Laser To Treat Vaginal Conditions FemTouch™ FemTouch™ is a fractional CO2 laser that addresses vaginal health-related conditions such as stress urinary incontinence, vaginal laxity, and vaginal atrophy. Lumenis® says that FemTouch promotes the restoration of the vaginal mucous epithelium layer. The laser is applied along the vaginal wall, resulting in gentle, controlled ablation and coagulation of the vaginal lining. Lumenis states that the FemTouch in-office procedure takes only a few minutes, is efficient (with 2 to 4 treatments needed), and requires no anesthesia or special postprocedural care. The treatment is associated with minimal discomfort for patients, according to Lumenis, and some women being treated with FemTouch report improvement in their condition after 1 or 2 procedures.
FemTouch is designed for use with the Lumenis AcuPulse™ MultiMode™ SuperPulse™ CO2 Laser System, offering 10 built-in treatment modes.
FOR MORE INFORMATION, VISIT: www.lumenis.com
According to the manufacturer’s instructions, a woman folds and inserts the cup in the lower vagina above the pelvic bone. She empties the cup 2 to 4 times per day and can use it overnight. Between uses, she rinses the cup with water and washes it with warm soapy water before reinsertion. When water is not available, toilet paper can be used for cleaning. For thorough cleaning, a woman can place the cup in boiling water then disinfect it with alcohol. Lunette should be cleaned after menses and stored in its own bag. The FDA recommends replacing the cup every 2 to 3 years.
Lunette is designed for all women, including those who have not had sexual intercourse and those who use an IUD or contraceptive ring (consult a physician). Lunette is available in 2 sizes: Model 1 is generally for those with light to moderate flow; Model 2 is recommended for normal or heavier flow. A detailed sizing guide is found on the website.
FOR MORE INFORMATION, VISIT: www.lunette.com/us
Detect Ovarian Cancer EarlyThe ROCA® Test from Abcodia offers early detection of ovarian cancer. Data reported from a large prospective randomized controlled study recently published in The Lancet demonstrate that a screening strategy using ROCA (Risk of Ovarian Cancer Algorithm) may reduce ovarian cancer mortality by an estimated 20%.
The ROCA Test uses a woman’s age, menopausal status, risk status, and serial blood measurements of CA 125 to produce a score that indicates current likelihood of having ovarian cancer. The initial risk assessment is then modified based on how closely a patient’s CA 125 profile matches the profiles seen in healthy women and women with ovarian cancer.
The test is intended for postmenopausal women between the ages of 50 and 85 years with no known risk factors other than age and for women between the ages of 35 and 85 years who are considered high risk due to family history of ovarian or breast cancer, have BRCA1 or BRCA2 gene mutations, or have Lynch Syndrome. The ROCA Test is now available in 15 states and the District of Columbia, and will be offered to additional areas of the United States in 2016.
After purchasing a ROCA Test online, the patient will receive an instructional kit, which she will take to her physician to review her medical history and sign a consent form. A blood sample will be drawn and sent to the ROCA Test laboratory. The physician will receive and share the test results with the patient. High-risk patients are encouraged to complete 3 tests per year.
FOR MORE INFORMATION, VISIT: www.rocatest.com
A semen sample can be collected at home and then shipped to the sperm banking facilities at Cleveland Clinic’s Andrology Center in Cleveland,Ohio. There, the sperm will be cryopreserved for as long as desired; an annual storage fee will be charged.
FOR MORE INFORMATION, VISIT: www.fairhavenhealth.com/nextgen-home-sperm-banking-kit.html